Our aim is to reach out to the globe within shortest possible time frame.
To promote this objective, not only we distribute and market our cardiovascular range of products globally through our distribution channels but we also undertake ‘contract manufacturing’& ‘formulation development ’of our wide range of generic products such as Nebibio which contain Nebivolol Hydrochloride equivalent to Nebivolol 5 mg.
This Nebibio COntains same active ingredient as Bystolic from Mylan Laboratories and Forest Laboratories.
Each uncoated tablet contains:
Nebivolol Hydrochloride equivalent to Nebivolol 5 mg
Nebivolol is a ß-adrenergic receptor blocking agent. It is a racemate of enantiomers L-nebivolol and d-nebivolol. Nebivolol is a long acting cardioselective beta blocker licensed for treatment of hypertension. It has vasodilatory property attributed to interaction with L-arginine/nitric oxide pathway. It thus enhances endothelial nitric oxide release.
- Stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients ≥ 70 years
Dosage and administration:
In hypertension the usual initial dose of Nebivolol is 5 mg once daily. Dosage reduction may be necessary in the elderly and in patients with hepatic or renal impairment.
Chronic heart failure in elderly
In heart failure the initial dose of Nebivolol is 1.25 mg once daily. If tolerated, the dose should be doubled every 1 to 2 weeks up to a maximum of 10 mg once daily.
•Heart block greater than first degree
•Decompensated cardiac failure
•Sick sinus syndrome (unless a permanent pacemaker is in place)
•Hypertensives with severe hepatic impairment (Child-Pugh >B)
•Heart failure patients with hepatic impairment
•Heart failure patients with severe renal insufficiency (serum creatinine 250μmol/L)
•Hypersensitivity to any component of this product
Alu-Alu Blister of 10 tablets.